ABSTRACT
BACKGROUND: Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH). METHODS: Patients with mild-to-moderate EH, selected at 44 sites in China from September 9, 2016, to December 7, 2018, were administered 240 mg allisartan isoproxil daily for 4 weeks. Patients with controlled blood pressure (BP) continued monotherapy for 8 weeks, others were randomly assigned (1:1) to A + D group (allisartan isoproxil 240 mg + indapamide 1.5 mg) or A + C group (allisartan isoproxil + amlodipine besylate 5 mg) for 8 weeks. BP were measured at week 4, 8 and 12. RESULTS: 2,126 patients were included in the analysis. After 12 weeks of treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased by 19.24 ± 12.02 and 10.63 ± 8.89 mm Hg, respectively, and the overall BP control rate was 78.56%. The sitting blood pressures (SBP/DBP) decreased by 19.12 ± 11.71/10.84 ± 8.73 mm Hg in patients with 12 weeks allisartan isoproxil monotherapy (both P < 0.0001). The BP reductions and control rates were comparable between A + D and A + C groups. 48 patients with monotherapy-controlled BP underwent ambulatory BP monitoring, with a mean decrease in ambulatory BP of 10.04 ± 10.87/5.50 ± 8.07 mm Hg after 12 weeks of treatment, and consistent reductions between day and night. SBP and DBP had trough-to-peak ratios of 64.64% and 62.63% and smoothness indices of 3.82 and 2.92, respectively. CONCLUSIONS: An allisartan isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH. PROJECT REGISTRATION NO: CTR20160138 (Registration and Information Disclosure Platform for China Drug Clinical Studies, http://www.chinadrugtrials.org.cn/index.html).
Subject(s)
Hypertension , Humans , Hypertension/diagnosis , Hypertension/drug therapy , Hypertension/chemically induced , Essential Hypertension/diagnosis , Essential Hypertension/drug therapy , Antihypertensive Agents/pharmacology , Imidazoles/therapeutic use , Amlodipine/adverse effects , Blood Pressure , Treatment Outcome , Double-Blind Method , TetrazolesABSTRACT
Many studies revealed that most cardio-cerebrovascular events were closely related to morning blood pressure surge (MBPS). The aim of our study was to investigate the relationship of MBPS with age and gender in hypertensive individuals, morning blood pressures of a total of 1100 cases with primary hypertension were analyzed. In our study, the morning systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and pulse pressure (PP) of hypertensives with MBPS were all higher (P<0.01). MBPS values were correlated with age (r=0.061, P<0.05). In hypertensive individuals with MBPS, morning SBP and PP increased while morning DBP decreased (P<0.01) as patients aged. Morning DBP and MAP of female patients were lower while morning PP was higher (P<0.01). These results indicated that MBPS was associated with both age and gender in hypertensive individuals.
